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Abstract
Background:To investigate the value of positron emission tomography (PET) and PET/computed tomography (CT) using ﬂuorine-
18-ﬂuorodeoxyglucose (18F-FDG) in the diagnosis, staging, restaging and recurrence monitoring of Ewing sarcoma family of tumors
(ESFTs), ameta-analysis was performed through systematically searching PubMed, Embase, andCochrane Central library to retrieve
articles.
Methods: After screening and diluting out the articles that met inclusion criteria to be used for statistical analysis the pooled
evaluation indexes including sensitivity, speciﬁcity, and diagnostic odd ratio (DOR) as well as the summary receiver operating
characteristic curve (SROC) were calculated involving diagnostic data (true positive, false positive, false negative, and true negative)
extracted from original studies.
Results:Screening determined that out of 2007, 23 studies involving a total of 524 patients were deemed viable for inclusion in the
meta-analysis. The results of the analysis showed that the sensitivity and speciﬁcity were at 86% and 80%, respectively. Additionally,
a satisfactory accuracy of 18F-FDG PET and PET/CT was observed in detecting ESFT recurrence, lung metastasis, and osseous
metastasis.
Conclusion: This meta-analysis suggests that 18F-FDG PET and PET/CT with an extremely high accuracy could be considered a
valuable method for detecting distant metastasis and post-operational recurrence of ESFT, which might have a profound impact on
the development of treatment protocols for ESFT.
Abbreviations: 18F-FDG = ﬂuorine-18-ﬂuorodeoxyglucose, AUC = the area under SROC, CT = computed tomography, DOR =
diagnostic odd ratio, ES = Ewing sarcoma, ESFT = Ewing sarcoma family of tumors, FN = false negative, FP = false positive, NLR =
negative likelihood ratio, PET = positron emission tomography, PLR = positive likelihood ratio, SROC = summary receiver operating
characteristic curve, TN = true negative, TP = true positive.
Keywords: 18F-FDG PET, Ewing sarcoma family of tumors, meta-analysis, metastasis, PET/CT, recurrence
1. Introduction most common primary bone sarcoma in children and adoles-The Ewing sarcoma family of tumors (ESFT) includes a series of
small, round-cell malignancies that are characterized by varying
degrees of neuroectodermal differentiation.[1] Ewing sarcoma
(ES) of bone is the most common type of ESFT and the secondEditor: Tamer Hassan.
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1cents.[2,3] Moreover, extra skeletal ES, Askin tumor (ES arising in
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chemotherapy, surgery and/or radiotherapy, has dramatically
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Approximately 25% of ES cases have detectable metastases at
presentation; on the other hand, approximately 30%∼40% of
patients will develop local or distant recurrence after treatment,
which would modify the outcome with a poor prognosis.[5–8]
Consequently, accurate initial staging, restaging and recurrence
monitoring play a crucial role in the treatment strategy for ESFT.
Traditional imaging modalities used to assess ESFT include
plain ﬁlm, computed tomography (CT), magnetic resonance
imaging, bone marrow biopsy and aspiration, bone scintigraphy,
and ﬂuorine-18-ﬂuorodeoxyglucose (18F-FDG) positron emis-
sion tomography (PET) or PET/CT. ESFT possess increased rate
of glycolysis. After intravenous administration of 18F-FDG, a
labeled glucose analog, accumulates in the malignant cells of
ESFT and is avidly retained. By detecting sites with high 18F-FDG
uptake, PET could identify malignant ESFT lesions. Hawkins
et al[9] suggested that 18F-FDG PET could be applied to assess the
histological response of ESFT after treatment and thus predict the
outcome. More recently, hybrid 18F-FDG PET/CT further
combined morphologic and metabolic information and achieved
better diagnostic performance. Although guidelines proposed by
National Comprehensive Cancer Network (NCCN) and the
Children’s Oncology Group Bone Tumor Committee both
recommend 18F-FDG PET as a considerable complementary
tool after the diagnosis of ES, the optimal or standardized
combination of staging tools is still unclear.[10,11]
Multiple trials have attempted to quantitatively measure the
accuracy of 18F-FDG PET and PET/CT in the diagnosis, staging
and recurrence monitoring of ESFT, but their results are
inconclusive. A previous meta-analysis suggested that 18F-FDG
PET and PET/CT have high pooled sensitivity and speciﬁcity
(0.96 and 0.92, respectively) in diagnosing ESFT. However, this
statistical analysis only included 5 studies and did not
differentiate sites of metastatic lesions or assess the accuracy
on lesion-based analysis.[12] Meanwhile, more eligible studies
were published in recent years. To draw a more precise
conclusion on this topic, a systematic review and meta-analysis
were conducted systematically involving published studies.2. Materials and methods
This investigation was conducted based on “the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA)” statement.[14] Ethical approval and patient consent
were not necessary, as the analysis was performed based on data
available in published literature.2.1. Article search and study selection
Previously published studies were collected using 2 approaches.
First, PubMed, Embase and the Cochrane Library were
systematically searched using the following keywords:1)
2)“Ewing” or “sarcoma” and
“PET” or “positron emission tomography”.No language or publication time limitation was imposed. The
last search was updated on February 28, 2018. Subsequently, the
bibliographies of relevant articles (reviews, editorials, included
trials and meta-analyses) were screened by hand to retrieve
additional studies.
Clinical studies appraising the performance of 18F-FDG PET
and PET/CT in the diagnosis, staging and recurrence monitoring
of patients with ESFT were eligible for inclusion in the meta-2analysis. The studies that provided data to calculate the
sensitivity and speciﬁcity were further included in the statistical
analysis. For articles containing overlapping data, the one
presenting the most comprehensive data or that was published
the most recently was chosen.
The exclusion criteria were as follows:1)
2)letters, reviews, editorials and other non-original articles;
trials with fewer than 5 patients with ESFT;3) congress proceedings; and
4) animal experiment.Two reviewers (LFX and ZQY) independently and repeatedly
evaluated the retrieved articles using the aforementioned criteria.
Ineligible articles were ﬁrst excluded by screening titles and
abstracts. Then, the full texts of remaining studies were
downloaded and reviewed in detail.
2.2. Data extraction and quality assessment
To reduce the bias, 3 reviewers (LFX, ZQY, and DJL)
independently performed this process. Any discrepancies were
resolved by consensus. For each included trial, the following basic
information was recorded: the ﬁrst author’s surname, year of
publication, original country, study design, number, age and
gender of participants, 18F-FDG PET or PET/CT, tracer dose,
methods of image interpretation and reference tests. With respect
to trials eligible for inclusion in the meta-analysis, examinations
or lesions were classiﬁed as true positive (TP), false positive (FP),
true negative (TN) or false negative (FN) cases according to their
18F-FDG statuses and the true outcome veriﬁed by reference tests.
The numbers of TPs, FPs, TNs, and FNs on lesion-based or
examination-based analysis were entered into a standardized
Excel ﬁle.
A quality assessment tool for the diagnostic accuracy studies
(QUADAS) was used to evaluate the methodological quality of
the included studies.[13] This tool contains 14 items, and each one
was described for 1 score. Any discrepancies were resolved by
consensus from a third investigator (DJL).
2.3. Statistical analysis
All statistical analyses were performed with Meta-disc 1.4. The
heterogeneity across studies was evaluated using I-square; for an
I-square<50%, the between-study heterogeneity was considered
not signiﬁcant. To quantitatively assess the performance of 18F-
FDG PET or PET/CT in the diagnosis, staging and recurrence
monitoring of ESFT, a random effect model was applied to
calculate the following pooled outcome estimates: sensitivity,
speciﬁcity, positive likelihood ratio (PLR), negative likelihood
ratio (NLR) and diagnostic odd ratio (DOR) (with 95%
conﬁdence interval) on examination-based or lesion-based
analysis. Moreover, the summary receiver operating characteris-
tic curve (SROC) with sensitivity as the x-coordinate and 1-
speciﬁcity as the y-coordinate was constructed. TheQ
∗
-index (the
point where sensitivity and speciﬁcity are equal on SROC) and
the area under SROC (AUC) could reﬂect the diagnostic accuracy
of 18F-FDG PET and PET/CT.
3. Results
3.1. Search results and study characteristics
The search of electronic databases and references yielded a total
of 2007 titles and abstracts. After careful selection, 23 articles
[15–36]
Figure 1. Selection ﬂow chart for studies included in the systematic review and meta-analysis.
Huang et al. Medicine (2018) 97:48 www.md-journal.compublished in English were included in the meta-analysis.
The detailed article search and study selection process were listed
in Figure 1.
Several studies sharing overlapped participants presented data
for different subgroup analyses. Therefore, all of these studies
were included in our research. The extracted data were presented
in Tables 1 and 2. As for the methodological quality, the review
authors’QUADAS judgments of included studies were presented
in Figure 2.
3.2. Lesion-based analysis
A total of 13 trials,[16,18–20,22,25–27,29–31,34,36] involving 689
lesions, were available to investigate the diagnostic performance
of 18F-FDG PET and PET/CT in ESFT. The pooled results were as
follows: sensitivity of 86% (95% CI of 82%–89%), speciﬁcity of
80% (95% CI of 75%–85%), PLR of 3.92 (95% CI of 3.08–
4.98), NLR of 0.19 (95% CI of 0.12–0.30) and DOR of 29.22
(95% CI of 16.49–51.78). There was no signiﬁcant between-
study heterogeneity for the sensitivity (I-square=0.001%).
Meanwhile, the Q
∗
-index and AUC were 0.8474 and 0.9147,
respectively (Fig. 3). Meanwhile, 9 studies[16,18–20,22,25–27,35]
involving a total of 170 ESFT described SUVmax uptake in the
primary lesions at initial staging, all being 18F-FDG-avid.
3.3. Examination-based analysis
3.3.1. Recurrence.A total of 5 trials[20,23,27,31,33] involving 123
examinations addressed ESFT recurrence (including local and
distant recurrence) using 18F-FDGPET or PET/CT. The threshold
effect was found in the provided examination-based data
(Spearman correlation coefﬁcient=0.895; P value= .040). The
pooled results for 18F-FDG PET and PET/CT to detect ESFT
recurrence were as follows: sensitivity of 93% (95% CI of 83%–398%), speciﬁcity of 90% (95% CI of 80%–96%), PLR of 8.53
(95% CI of 4.12–17.65), NLR of 0.09 (95% CI of 0.04–0.21),
and DOR of 109.98 (95% CI of 30.66–394.54). There was no
signiﬁcant between-study heterogeneity for the included outcome
estimates (all I-squares=0). Meanwhile, the Q
∗
-index and AUC
were 0.9129 and 0.9656, respectively (Fig. 4).
Subgroup analysis was performed exclusively on the basis of
PET/CT data. A total of 4 trials[23,27,31,33] involving 106
examinations addressed ESFT recurrence using 18F-FDG PET/
CT. The pooled results for 18F-FDG PET to detect ESFT
recurrence were as follows: sensitivity of 94% (95% CI of 83%–
98%), speciﬁcity of 91% (95% CI of 80%–97%), PLR of 8.82
(95% CI of 4.00–19.45), NLR of 0.08 (95% CI of 0.03–0.22)
and DOR of 128.49 (95%CI of 31.15–529.99). There was no
signiﬁcant between-study heterogeneity for the included outcome
estimates (all I-squares=0). Meanwhile, the Q
∗
-index and AUC
were 0.9198 and 0.9700, respectively (Fig. 5).
3.3.2. Lungmetastasis.On the examination-based level, a total
of 8 trials[5,17,23,26,29–31,33] involving 278 examinations investi-
gated lung metastasis of ESFT using 18F-FDG PET or PET/CT.
The pooled results for 18F-FDG PET and PET/CT to detect ESFT
recurrence were as follows: sensitivity of 72% (95% CI of 57%–
84%), speciﬁcity of 97% (95% CI of 94%–99%), PLR of 13.51
(95% CI of 6.22–29.34), NLR of 0.38 (95% CI of 0.20–0.74)
and DOR of 60.55 (95% CI of 14.41–254.39). There was no
signiﬁcant between-study heterogeneity for the included outcome
estimates. The Q
∗
-index and AUC were 0.8861 and 0.9467,
respectively (Fig. 6).
Subgroup analysis was also performed exclusively on the basis
of PET/CT data. On the examination-based level, a total of 6
trials[5,23,26,30,31,33] involving 189 examinations investigated
lung metastasis of ESFT using 18F-FDG PET/CT. The pooled
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Table 2
Diagnosis accuracy data on each examination– or lesion–based analysis.
Study, year Total TP FP FN TN Lesion sites Analysis level
Schulte, 2000 14 14 0 0 0 Primary lesion Lesion–based
Antonia, 2002 8 7 0 1 0 Primary lesion Lesion–based
Franzius, 2002 21 21 0 0 0 Primary lesion Lesion–based
Gyorke, 2006 16 16 0 0 0 Primary lesion Lesion–based
Kneisl, 2006 17 17 0 0 0 Primary lesion Lesion–based
Tateishi, 2007 20 20 0 0 0 Primary lesion Lesion–based
Volker, 2007 23 23 0 0 0 Primary lesion Lesion–based
Charest, 2009 9 9 0 0 0 Primary lesion Lesion–based
Bailly, 2017 31 31 0 0 0 Primary lesion Lesion–based
Kasalak, 2018 20 3 0 1 16 Primary lesion Lesion–based
Gyorke, 2006 17 8 1 1 7 Recurrence Examination–based
Arush, 2007 9 5 0 0 4 Recurrence Examination–based
Charest, 2009 13 3 0 0 10 Recurrence Examination–based
Ozkan, 2012 13 3 0 0 10 Recurrence Examination–based
Sharma, 2013 71 38 4 2 27 Recurrence Examination–based
Fruanzius, 2001 61 9 4 7 41 Lung Examination–based
Arush, 2007 9 1 0 0 8 Lung Examination–based
Volker, 2007 23 1 0 2 20 Lung Examination–based
Mody, 2010 28 1 1 1 25 Lung Examination–based
Cistaro, 2012 13 2 0 0 11 Lung Examination–based
Ozkan, 2012 13 0 0 0 13 Lung Examination–based
Sharma, 2013 71 8 0 0 63 Lung Examination–based
Ulaner, 2014 60 8 0 0 52 Lung Examination–based
Fruanzius, 2000 66 19 2 0 45 Bone Examination–based
Arush, 2007 13 3 0 1 9 Bone Examination–based
Volker, 2007 23 6 0 0 17 Bone Examination–based
Ozkan, 2012 13 0 0 0 13 Bone Examination–based
Sharma, 2013 71 9 0 0 62 Bone Examination–based
Ulaner, 2014 60 11 0 1 48 Bone Examination–based
Arush, 2007 9 1 0 0 8 Lymph node Examination–based
Tateishi, 2007 20 2 0 0 18 Lymph node Examination–based
Volker, 2007 23 1 0 0 22 Lymph node Examination–based
Ozkan, 2012 13 3 0 0 10 Lymph node Examination–based
Sharma, 2013 70 7 1 0 62 Lymph node Examination–based
Ulaner, 2014 60 3 1 0 56 Lymph node Examination–based
Schulte, 2000 14 14 0 0 0 All lesions Lesion–based
Antonia, 2002 8 7 0 1 0 All lesions Lesion–based
Franzius, 2002 21 21 0 0 0 All lesions Lesion–based
Gyorke, 2006 163 113 2 41 7 All lesions Lesion–based
Kneisl, 2006 17 17 0 0 0 All lesions Lesion–based
Tateishi, 2007 20 20 0 0 0 All lesions Lesion–based
Volker, 2007 23 23 0 0 0 All lesions Lesion–based
Charest, 2009 9 9 0 0 0 All lesions Lesion–based
Mody, 2010 28 13 1 2 12 All lesions Lesion–based
Cistaro, 2012 24 2 0 0 22 All lesions Lesion–based
Ozkan, 2012 13 1 0 0 12 All lesions Lesion–based
Quartuccio, 2015 311 102 44 11 154 All lesions Lesion–based
Kasalak, 2018 38 5 0 2 31 All lesions Lesion-based
FN= false negative, FP= false positive, TN= true negative, TP= true positive.
Huang et al. Medicine (2018) 97:48 www.md-journal.comresults for F-FDG PET and PET/CT to detect ESFT recurrence
were as follows: sensitivity of 82% (95% CI of 63%–94%),
speciﬁcity of 98% (95% CI of 95%–100%), PLR of 32.04 (95%
CI of 9.85–104.24), NLR of 0.24 (95% CI of 0.06–0.89) and
DOR of 160.70 (95% CI of 30.68–841.61). There was no
signiﬁcant between-study heterogeneity for the included outcome
estimates. The Q
∗
-index and AUC were 0.9807 and 0.9972,
respectively (Fig. 7).
3.3.3. Bone metastasis. A total of 6 trials[5,15,23,26,31,33]
involving 246 examinations addressed osseous metastasis
of ESFT using 18F-FDG PET or PET/CT. The pooled results5for F-FDG PET and PET/CT to detect bone metastasis of ESFT
were as follows: sensitivity of 91% (95% CI of 80% to 97%),
speciﬁcity of 98% (95% CI of 94%–99%), PLR of 26.60 (95%
CI of 11.06–63.97), NLR of 0.15 (95% CI of 0.05–0.39) and
DOR of 347.37 (95% CI of 78.50–1537.18). There was no
signiﬁcant between-study heterogeneity for the included outcome
estimates. The Q
∗
-index and AUC were 0.9492 and 0.9859,
respectively (Fig. 8).
Subgroup analysis was performed exclusively on the basis of
PET/CT data. A total of 5 trials[5,23,26,31,33] involving 180
examinations addressed osseous metastasis of ESFT using 18F-
FDG PET/CT. The pooled results for 18F-FDG PET and PET/CT
Figure 2. Review authors’ QUADAS judgments about each domain presented
as percentages across included studies.
Huang et al. Medicine (2018) 97:48 Medicineto detect bone metastasis of ESFT were as follows: sensitivity of
88% (95% CI of 72%–96%), speciﬁcity of 98% (95% CI of
95%–100%), PLR of 39.34 (95% CI of 10.99–140.84), NLR of
0.19 (95% CI of 0.08–0.45) and DOR of 279.65 (95% CI of
51.19–1527.81) (Fig. 9). There was no signiﬁcant between-study
heterogeneity for the included outcome estimates. The Q
∗
-index
and AUC were 0.9780 and 0.9965, respectively (Fig. 9).
3.3.4. Lymph metastasis. Only 6 studies[5,23,25,26,31,33] involv-
ing 17 TP examinations and no FN examinations were included
in this study. This result should be interpreted cautiously.4. Discussion
Results of the diagnostic accuracy of 18F-FDG PET and PET/CT
in ESFT remain inconclusive. One previous study [37] tried to
further clarify this issue, but none of the included studies
speciﬁcally aimed at ESFT and did not statistically analyze the6retrieved data. To the best of our knowledge, there is no meta-
analysis comprehensively evaluating the performance of 18F-FDG
PET and PET/CT in the diagnosis, staging and recurrence
monitoring of ESFT. In this meta-analysis, this issue was
statistically investigated by analyzing data collected from 23
studies on the lesion- or examination-based level.
ESFT is rather rare. Approximately 225 cases of ESFT in
patients younger than 20 years of age are diagnosed in North
America annually.[38] No blood, urine or imaging tests can
speciﬁcally identify ESFT, and the gold standard for diagnosing
ESFT is still pathological examination. In 2000, Franzius et al
ﬁrst reported the value of PET in the diagnosis of Ewing’s
sarcoma.[15] On examination-based analysis, no FN cases and
only 2 FP cases were observed (n=66), and the sensitivity,
speciﬁcity, and accuracy were 100%, 96%, and 97%, respec-
tively. Previous studies suggested that the SUVmax of ESFT is
normally high.[39] In our collected data, a total of 139 primary
ESFT lesions retrieved from 8 studies were classiﬁed as 18F-FDG-
avid. However, to be clear, as overlapping SUV exist in different
sarcoma types, including benign lesions, 18F-FDG PET and PET/
CT cannot distinctly differentiate between ESFT and other
malignant tumors, and they are mainly used as staging tools.
Although the prognosis of ESFT has greatly improved,
approximately 30%∼40% of patients will develop recurrent
disease after treatment. The outcome of those patients is very
poor and has an overall 5-year survival of less than 15%.[40,41]
Detecting patients with recurrence and improving the diagnostic
accuracy at early stage may prompt effective treatment. For
examination-based data, the high accuracy of 18F-FDG PET and
PET/CT for detecting recurrence (local or distant) of ESFT was
demonstrated; the sensitivity, speciﬁcity, and DOR were 0.93,
0.90, and 109.98, respectively, which is similar to the conclusions
for other recurrent malignant tumors.[42,43] Especially, the
sensitivity, speciﬁcity, and DOR of 18F-FDG PET/CT solely for
detecting recurrence (local or distant) of ESFT were 0.94, 0.91,
and 128.49.
18F-FDG PET/CT should be performed before a diagnostic
biopsy site is chosen in patients with a high clinical suspicion of
aggressive, advanced tumor. One retrospective study[44] involv-
ing 51 advanced lung cancer patients aimed to evaluate the safety
and efﬁcacy of 18F-FDG PET/CT in bone metastases lesions. No
serious complications were encountered, which demonstrated
that PET/CT-guided percutaneous biopsy of 18F-FDG-avid bone
metastases is an effective and safe method that yields a high
diagnostic success rate. Salem U and his co-authors reported that
a high SUVmax of pre-therapeutic and post-therapeutic FDG
PET/CT correlated with overall survival and that a pre-
therapeutic SUVmax>11.6 decreased the overall survival and
progression-free survival in patients with ES. They revealed that
18F-FDG PET/CT can be used as a prognostic indicator of
survival in primary ES.[45] The most crucial indicator for an
adverse prognosis of ESFT is the presence of metastatic disease.
Approximately 25% of patients with ESFT already have
detectable metastasis at diagnosis. Cotterill SJ et al analyzed
975 Ewing sarcoma patients from the European Intergroup
Cooperative Group and observed that their survival rate had a
good correlation with the number and location of metastatic
lesions.[46] Therefore, the prognostic staging and restaging of
ESFT plays a vital role in developing treatment plans and
eventually ameliorates the outcome of patients. Although several
imaging modalities, including chest CT, bone scintigraphy, 18F-
FDG PET, and PET/CT, are recommended in the guidelines, the
best imaging strategy remains unclear. An advantage of 18F-FDG
Figure 3. Performance of 18F-FDG PET/CT to detect all ESFT lesions on lesion-based analysis: a. pooled sensitivity, b. pooled speciﬁcity, c. pooled diagnostic
odds ratio, and d. SROC with the Q
∗
-index. SROC=summary receiver operating characteristic curve.
Figure 4. Performance of 18F-FDG PET and PET/CT to detect recurrence of ESFT on an examination-based analysis: a. pooled sensitivity, b. pooled speciﬁcity, c.
pooled diagnostic odds ratio, and d. SROC with the Q
∗
-index. ESFT=Ewing’s sarcoma family of tumor, 18F-FDG=ﬂuorine-18-ﬂuorodeoxyglucose, PET/CT=
positron emission tomography/computed tomography, SROC=summary receiver operating characteristic curve.
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Figure 5. Performance of 18F-FDG PET/CT to detect recurrence of ESFT on an examination-based analysis: a. pooled sensitivity, b. pooled speciﬁcity, c. pooled
diagnostic odds ratio, and d. SROC with the Q
∗
-index. SROC=summary receiver operating characteristic curve.
Figure 6. Performance of 18F-FDG PET and PET/CT to detect lung metastasis of ESFT on examination-based analysis: a. pooled sensitivity, b. pooled speciﬁcity,
c. pooled diagnostic odds ratio, and d. SROC with the Q
∗
-index. ESFT=Ewing’s sarcoma family of tumor, 18F-FDG=ﬂuorine-18-ﬂuorodeoxyglucose, PET/CT=
positron emission tomography/computed tomography, SROC=summary receiver operating characteristic curve.
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Figure 7. Performance of 18F-FDG PET/CT to detect lung metastasis of ESFT on examination-based analysis: a. pooled sensitivity, b. pooled speciﬁcity, c. pooled
diagnostic odds ratio, and d. SROC with the Q
∗
-index. ESFT=Ewing’s sarcoma family of tumor, 18F-FDG=ﬂuorine-18-ﬂuorodeoxyglucose, PET/CT=positron
emission tomography/computed tomography, SROC=summary receiver operating characteristic curve.
Figure 8. Performance of 18F-FDG PET and PET/CT to detect osseous metastasis of ESFT on an examination-based analysis: a. pooled sensitivity, b. pooled
speciﬁcity, c. pooled diagnostic odds ratio, and d. SROC with the Q
∗
-index. ESFT=Ewing’s sarcoma family of tumor, 18F-FDG=ﬂuorine-18-ﬂuorodeoxyglucose,
PET/CT=positron emission tomography/computed tomography, SROC=summary receiver operating characteristic curve.
Huang et al. Medicine (2018) 97:48 www.md-journal.com
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Figure 9. Performance of 18F-FDG PET/CT to detect osseous metastasis of ESFT on an examination-based analysis: a. pooled sensitivity, b. pooled speciﬁcity, c.
pooled diagnostic odds ratio, and d. SROC with the Q
∗
-index. ESFT=Ewing’s sarcoma family of tumor, 18F-FDG=ﬂuorine-18-ﬂuorodeoxyglucose, PET/CT=
positron emission tomography/computed tomography, SROC=summary receiver operating characteristic curve.
Huang et al. Medicine (2018) 97:48 MedicinePET and PET/CT is that they can be used to identify systematic
metastasis. In this investigation, we further performed examina-
tion analyses according to the metastatic sites.
Most metastatic ESFT lesions occur in lung.[38] Compared to
patientswith bone-onlymetastases or a combination of lung and
bone metastasis, patients with lung involvement have a better
prognosis.[46] Bone is the second most frequently involved site
for metastatic ESFT lesions.[38] DOR, as an indicator of
diagnostic accuracy, reﬂects the association between the
relevant disease, and test results by calculating a single special
ratio that combines the sensitivity and speciﬁcity. A higher DOR
(range from 0 to inﬁnity) stands for a more favorable diagnostic
accuracy. In this respect, this meta-analysis revealed that
diagnosing lung metastasis of ESFT using 18F-FDG-PET and
PET/CT does have a good accuracy with DORs of 60.55 (95%
CI of 14.41–254.39) as for bone metastasis with DORs of
347.37 (95% CI of 78.50–1537.18). A similar trend was
observed on SROC with AUCs of 0.9467 and 0.9859 for lung
and bone metastases, respectively. Considering the high
accuracy of 18F-FDG PET and PET/CT in detecting the osseous
metastasis of ESFT, bone scintigraphy may be omitted from the
staging of ESFT. Metastasis to the bone marrow, lymph nodes,
and other sites, although uncommon, is also observed in patients
with ESFT. In retrieved patients, all metastatic lesions in lymph
nodes were identiﬁed.
Several subgroup-analyses were made based exclusively on
PET/CT data about diagnosis of recurrence, lung metastases, and
osseous metastases. Although seemingly the results of PET/CT
were better compared with PET, we could not draw a distinct
conclusion due to the overlapping conﬁdence intervals.
The reliability and innovation of this research rely on the large
sample size, uniform statistical processing, and elaborate10subgroup analysis, which will help us obtain a more
comprehensive understanding of the performance of 18F-FDG
PET and PET/CT in the diagnosis, staging, and recurrence
monitoring of ESFT. However, some limitations in this study
merited consideration. First, this is a meta-analysis and systemic
review; we analyzed the questions on the study level instead of
on the patient level. Consequently, underestimation/overesti-
mation was unavoidable. Second, there was methodological
variability in the included trials, such as the method for
measuring the 18F-FDG uptake, cutoff for determining the
lesion positivity, reference standards tests and duration of
follow-up. In addition, some studies evaluated 18F-FDG PET,
while others evaluated PET/CT. Last but not least, several
subgroup analyses were based on a small number of studies,
which could reduce their power. We made our best effort to
extract data on the sensitivity and speciﬁcity from 3 levels of
analysis, but in some subgroups, sufﬁcient data were unavail-
able for quantitative statistics.5. Conclusion
In conclusion, this systemic review and meta-analysis indicated
high sensitivity for 18F-FDG PET and PET/CT in identifying
primary ESFT lesions. Moreover, 18F-FDG PET and PET/CT,
with extremely high accuracy, could be considered valuable
methods for detecting metastasis and post-operational recur-
rence, which might have a profound impact on the development
of treatment protocols for ESFT. Nevertheless, considering the
possibility of false-positive and false-negative cases, pathological
examination or long-term follow-up should be performed for 18F-
FDG-avid ESFT lesions. Large-scale, randomized, prospective
trials are still needed to further warrant conclusions.
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